Zacks.com featured highlights include Cencora, Raymond James and Cintas

Published on 26 Nov 2024 on Zacks · via Yahoo Finance

These factors are likely to have favored the stock’s growth. You can see the complete list of...

Read the rest of the article

Start tracking your investments with Statfolio

The significant improvement in patency rates for AVG patients via Merit Medical's WRAPSODY device...

Zacks · via Yahoo Finance 27 Nov 2024

ETF Bets ETF picks are all top-ranked. SPDR Dow Jones Industrial Average ETF DIA – Zacks Rank #1...

Zacks · via Yahoo Finance 26 Nov 2024

These factors are likely to have favored the stock’s growth. You can see the complete list of...

Zacks · via Yahoo Finance 26 Nov 2024

These factors are likely to have favored the stock’s growth. Risk Factors COR’s gross margin...

Zacks · via Yahoo Finance 22 Nov 2024

Steven Collis, Executive Chairman of Cencora, Inc. (NYSE:COR), recently sold 21,509 shares of the...

Investing.com 22 Nov 2024

The availability of the FDA-approved drug via McKesson's cell and gene therapies business is...

Zacks · via Yahoo Finance 21 Nov 2024

The Zacks Consensus Estimate for the year’s adjusted earnings is pegged at $5.44 per share. Our T...

Zacks · via Yahoo Finance 19 Nov 2024

Patterson Companies, Inc.'s PDCO subsidiary, Patterson Dental Supply, Inc., recently announced an...

Zacks · via Yahoo Finance 19 Nov 2024

The stock is up 15.2% year-to-date. The consensus estimate for Halozyme Therapeutics' current yea...

Zacks · via Yahoo Finance 19 Nov 2024

Walgreens reports better-than-expected earnings and revenues in the fourth quarter of fiscal 2024.

Zacks 15 Oct 2024